NCT07030621View on ClinicalTrials.gov

Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

436

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

January 31, 2028

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Semaglutide 0.5 mg

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) analog, which has been found to have neuroprotective effects.

DRUG

Normal Saline

Normal saline is the placebo drug.

Trial Locations (1)

200127

Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER